- Home
- DAWN vs PRA Comparison
DAWN vs PRA Comparison
Compare DAWN & PRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DAWN | PRA |
|---|---|---|
| Founded | 2018 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DAWN | PRA |
|---|---|---|
| Price | $12.02 | $24.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | ★ $27.56 | $22.50 |
| AVG Volume (30 Days) | ★ 1.6M | 534.2K |
| Earning Date | 04-13-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.96 | N/A |
| EPS | N/A | ★ 0.99 |
| Revenue | $131,161,000.00 | ★ $1,098,028,000.00 |
| Revenue This Year | $18.59 | N/A |
| Revenue Next Year | $49.98 | $1.24 |
| P/E Ratio | ★ N/A | $71.81 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.64 | $14.50 |
| 52 Week High | $13.20 | $24.66 |
Technical Indicators
Market Signals| Indicator | DAWN | PRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 55.47 |
| Support Level | $10.07 | $23.88 |
| Resistance Level | $13.20 | $24.64 |
| Average True Range (ATR) | 0.67 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 92.16 | 43.21 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.